Table 3.
Hematotoxicity and adverse event after TACE-2
| Hematotoxicity | Grade | SIG (n = 238) | LIG (n = 238) | P |
|---|---|---|---|---|
| Leukopenia | 1 | 14 | 21 | |
| 2 | 4 | 9 | ||
| 3 | 0 | 2 | 0.368‡ | |
| Anemia | 1 | 67 | 80 | |
| 2 | 33 | 36 | ||
| 3+4 | 5 | 10 | 0.960 | |
| Thrombocytopenia | 1 | 29 | 31 | |
| 2 | 35 | 23 | ||
| 3+4 | 10 | 11 | 0.065 | |
| Hypoalbuminemia | 1 | 79 | 86 | |
| 2 | 19 | 20 | 0.925 | |
| TBIL increased | 1 | 101 | 0 | |
| 2 | 78 | 4 | 0.073‡ | |
| Adverse events | SIG (n = 238) | LIG (n = 238) | P | |
| Hyperpyrexia | 42 (17.6%) | 55 (23.1%) | 0.139 | |
| Vomit | 20 (8.4%) | 21 (8.8%) | 0.870 | |
| Myelosuppression | 1 (0.4%) | 2 (0.8%) | 1.000‡ | |
| Hypohepatia | 2 (0.8%) | 2 (0.8%) | 1.000‡ | |
| Cholangitis | 1 (0.4%) | 0 | 1.000† | |
| Pulmonary infection | 2 (0.8%) | 0 | 1.000‡ | |
| Gastrointestinal bleeding | 1 (0.4%) | 0 | 1.000 | |
| Hepatapostema | 1 (0.4%) | 0 | 1.000† | |
| Total | 70 (29.4%) | 80 (33.6%) | 0.324 | |
* The grade of adverse event were evalued according to the common terminology criteria for adverse events (CTCAE) version 4.0
†: Fisher exact test.
‡: χ2 test with a continuity correction.
TACE-2, the second session transarterial chemoembolization
SIG, short-interval group; LIG, long-interval group